Cancer nanomedicine: is targeting our target?
The majority of nanomedicines in (pre) clinical trials are based on established drugs, such
as doxorubicin and paclitaxel. Does that make sense? To some extent yes, because a lot of …
as doxorubicin and paclitaxel. Does that make sense? To some extent yes, because a lot of …
Strategies for advancing cancer nanomedicine
VP Chauhan, RK Jain - Nature materials, 2013 - nature.com
Cancer nanomedicines approved so far minimize toxicity, but their efficacy is often limited by
physiological barriers posed by the tumour microenvironment. Here, we discuss how these …
physiological barriers posed by the tumour microenvironment. Here, we discuss how these …
Nanomedicine tumor targeting
T Lammers - Advanced Materials, 2024 - Wiley Online Library
Nanomedicines are extensively explored for cancer therapy. By delivering drug molecules
more efficiently to pathological sites and by attenuating their accumulation in healthy organs …
more efficiently to pathological sites and by attenuating their accumulation in healthy organs …
Obstacles and opportunities in a forward vision for cancer nanomedicine
I de Lázaro, DJ Mooney - Nature materials, 2021 - nature.com
Cancer nanomedicines were initially envisioned as magic bullets, travelling through the
circulation to target tumours while sparing healthy tissues the toxicity of classic …
circulation to target tumours while sparing healthy tissues the toxicity of classic …
Cancer nanotechnology: current status and perspectives
JA Kemp, YJ Kwon - Nano convergence, 2021 - Springer
Modern medicine has been waging a war on cancer for nearly a century with no tangible
end in sight. Cancer treatments have significantly progressed, but the need to increase …
end in sight. Cancer treatments have significantly progressed, but the need to increase …
Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments
CM Dawidczyk, LM Russell, PC Searson - Frontiers in chemistry, 2014 - frontiersin.org
The ability to efficiently deliver a drug or gene to a tumor site is dependent on a wide range
of factors including circulation time, interactions with the mononuclear phagocyte system …
of factors including circulation time, interactions with the mononuclear phagocyte system …
Cancer nanomedicine: emerging strategies and therapeutic potentials
M Xu, X Han, H Xiong, Y Gao, B Xu, G Zhu, J Li - Molecules, 2023 - mdpi.com
Cancer continues to pose a severe threat to global health, making pursuing effective
treatments more critical than ever. Traditional therapies, although pivotal in managing …
treatments more critical than ever. Traditional therapies, although pivotal in managing …
Cancer nanomedicine: progress, challenges and opportunities
J Shi, PW Kantoff, R Wooster, OC Farokhzad - Nature reviews cancer, 2017 - nature.com
The intrinsic limits of conventional cancer therapies prompted the development and
application of various nanotechnologies for more effective and safer cancer treatment …
application of various nanotechnologies for more effective and safer cancer treatment …
Nanotherapy for cancer: targeting and multifunctionality in the future of cancer therapies
A Ediriwickrema, WM Saltzman - ACS biomaterials science & …, 2015 - ACS Publications
Cancer continues to be a prevalent and lethal disease, despite advances in tumor biology
research and chemotherapy development. Major obstacles in cancer treatment arise from …
research and chemotherapy development. Major obstacles in cancer treatment arise from …